BioAtla, Inc. Profile Avatar - Palmy Investing

BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conj…

Biotechnology
US, San Diego [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of BCAB's Analysis
CIK: 1826892 CUSIP: 09077B104 ISIN: US09077B1044 LEI: - UEI: -
Secondary Listings
BCAB has no secondary listings inside our databases.